This software bot accelerates and streamlines the scheduling of hundreds of thousands of patient appointments to receive the two-shot vaccine for COVID-19.
Clalit Health Services, the largest healthcare maintenance organization in Israel, has already used the Kryon V-Bot to schedule more than 100,000 vaccine appointments per day.
Israel leads the world in COVID vaccinations and having already vaccinated 30% of its eight m citizens.
The logistical problems facing healthcare organizations attempting a controlled COVID-19 vaccine roll-out are astounding.
Many hospitals, healthcare providers and HMOs receive vaccines with little notice, placing enormous stress on support staff to schedule last minute appointments and use every available dose.
By automating scheduling based on eligibility criteria, the burden is lifted allowing them to focus on areas that require a human touch, like patient care and service.
Kryon is offering the V-Bot to all healthcare providers to expedite the required double-appointment setting. The purchase of Kryon V-Bot includes an unlimited amount of software bots to assist in the mass scheduling.
Further, Kryon will also customize the automation workflow of an organization's patient scheduling process based on an individual organization's structure and needs.
Kryon is in enterprise automation, offering the only platform on the market which encompasses both Process Discovery technology and Robotic Process Automation (RPA).
The Kryon Full-Cycle Automation solution maximizes ROI by 352% according to Forrester Research and cuts RPA implementation time by up to 80%.
Powered by proprietary AI technology, Kryon Process Discovery automatically generates a comprehensive picture of business processes, evaluates them, and recommends which ones to automate.
Kryon offers desktop-based attended RPA, virtual-machine-based unattended RPA, or a hybrid combination of both. The company's award-winning suite is used by enterprises worldwide, including AIG, Allianz, Deutsche Telekom, EY, Ferring Pharmaceuticals, HP, Microsoft, Santander Bank, Singtel, Verizon, and Wyndham Hotel Group.
Neurocrine Biosciences announces presentation of Osavampator Phase 2 data at Psych Congress 2025
Ascletis presents ASC30 study results at EASD Annual Meeting
Three WuXi Biologics manufacturing facilities receive GMP certification from Turkish regulator
VarmX secures strategic collaboration and option agreement with CSL for novel coagulation therapy
Avidity Biosciences closes USD690m public offering of common stock
Akeso's ligufalimab (CD47 mAb) granted FDA Orphan Drug Designation for AML
Forte Biosciences highlights positive FB102 data in celiac disease at Tampere Symposium
SureSpace Launches in Dubai to Tackle Doomscrolling and Redefine Social Networking
Kodiak reports positive APEX data for KSI-101 in macular edema secondary to inflammation
Biophytis secures Brazilian funding and partnerships for obesity Phase 2 trial
Phrontline Biopharma doses first patient in TJ101 Phase 1 clinical trial
Gene Solutions' mitochondrial therapy platform targeting neurological diseases secures patent
Zhimeng Biopharma's investigational drug gains Phase 2 epilepsy clinical trial approval in China
Avidity Biosciences prices upsized common stock public offering